150 related articles for article (PubMed ID: 36952298)
1. Urologist-perceived barriers and perspectives on the underuse of sacral neuromodulation for overactive bladder in Canada.
Gariscsak P; Gray G; Steele S; Elterman D; Doiron RC
Can Urol Assoc J; 2023 Jun; 17(6):E165-E171. PubMed ID: 36952298
[TBL] [Abstract][Full Text] [Related]
2. Urologists' referral attitude for sacral neuromodulation for treating refractory idiopathic overactive bladder syndrome: discrete choice experiment.
Kessler TM; Maric A; Mordasini L; Wöllner J; Pannek J; Mehnert U; van Kerrebroeck PE; Bachmann LM
Neurourol Urodyn; 2014 Nov; 33(8):1240-6. PubMed ID: 24127359
[TBL] [Abstract][Full Text] [Related]
3. Variable frequency stimulation of sacral neuromodulation in black-zone overactive bladder patients: a case report.
Meng L; Diao T; Wang M; Liu X; Zhang W; Tian Z; Wang J; Zhang Y
Transl Androl Urol; 2020 Dec; 9(6):2842-2847. PubMed ID: 33457256
[TBL] [Abstract][Full Text] [Related]
4. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator.
Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J
Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786
[TBL] [Abstract][Full Text] [Related]
5. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
[TBL] [Abstract][Full Text] [Related]
6. Do patients experience decisional regret after sacral neuromodulation for refractory overactive bladder?
Kessler L; Illinsky D; Laudano M; Abraham NE
Neurourol Urodyn; 2024 Jan; 43(1):22-30. PubMed ID: 37830272
[TBL] [Abstract][Full Text] [Related]
7. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
[TBL] [Abstract][Full Text] [Related]
8. What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder.
Oelke M; Addali M; Reisenauer C
Arch Gynecol Obstet; 2019 May; 299(5):1243-1252. PubMed ID: 30941558
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation.
Trinh H; Irish V; Diaz M; Atiemo H
Int Neurourol J; 2019 Sep; 23(3):226-233. PubMed ID: 31607102
[TBL] [Abstract][Full Text] [Related]
10. Sacral neuromodulation system for treating refractory overactive bladder.
Phillips A
Br J Nurs; 2020 Oct; 29(18):S30-S37. PubMed ID: 33035097
[TBL] [Abstract][Full Text] [Related]
11. Variable- versus constant-frequency sacral neuromodulation in black-zone overactive bladder patients: a study protocol for a multicenter, prospective, randomized, blind, self-controlled trial.
Meng L; Tian Z; Diao T; Wang M; Liu X; Zhang W; Wang J; Zhang Y
Transl Androl Urol; 2021 Jan; 10(1):504-511. PubMed ID: 33532338
[TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients.
Reekmans M; Janssen JMW; Vrijens DMJ; Smits MAC; van Koeveringe GA; Van Kerrebroeck PEVA
Neurourol Urodyn; 2021 Jun; 40(5):1120-1125. PubMed ID: 33829519
[TBL] [Abstract][Full Text] [Related]
13. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
Kaaki B; Gupta D
PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
[TBL] [Abstract][Full Text] [Related]
14. Cognitive impairment does not impact sacral neuromodulation implant rates for overactive bladder.
Zillioux J; Lewis KC; Hettel D; Goldman HB; Vasavada SP; Gill BC
Neurourol Urodyn; 2023 Mar; 42(3):623-630. PubMed ID: 36701189
[TBL] [Abstract][Full Text] [Related]
15. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis.
Yang G; Xu Y; Qu G; Zhang Y
PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049
[TBL] [Abstract][Full Text] [Related]
16. Do Failure of Posterior Tibial Nerve Stimulation Precludes to Use Sacral Neuromodulation in Patient With Overactive Bladder?
Berthelot LP; Peyronnet B; Cornu JN; Aublé A; Brassart E; Bigot P; Carrouget J
Int Neurourol J; 2019 Dec; 23(4):287-293. PubMed ID: 31905275
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy of sacral neuromodulation in the treatment of voiding dysfunction after endometriosis surgery.
Aublé A; Gazdovich S; Dégremont S; Pfister C; Roman H; Bridoux V; Leroi AM; Cornu JN
Prog Urol; 2023 Dec; 33(17):1073-1082. PubMed ID: 37951811
[TBL] [Abstract][Full Text] [Related]
18. [Functional results and satisfaction in 44 patients after implantation of a NS3-type sacral neurostimulator for refractory idiopathic overactive bladder followed at 43 months, single-center series].
Msika J; Kalantan M; Larre S; Leon P
Prog Urol; 2021 Oct; 31(12):725-731. PubMed ID: 33962849
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective.
Hassouna MM; Sadri H
Can Urol Assoc J; 2015; 9(7-8):242-7. PubMed ID: 26316906
[TBL] [Abstract][Full Text] [Related]
20. Sacral neuromodulation: Rechargeable versus non-rechargeable device. What would the patient preferences be in France?
Gamé X; Ruffion A; Cornu JN; Phé V; Peyronnet B; Perrouin-Verbe MA; Aublant C; Adé A; Chartier-Kastler E
Prog Urol; 2022 Sep; 32(10):672-680. PubMed ID: 35752523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
